- Home
- ZENV vs INMB Comparison
ZENV vs INMB Comparison
Compare ZENV & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- INMB
- Stock Information
- Founded
- ZENV 2005
- INMB 2015
- Country
- ZENV Brazil
- INMB United States
- Employees
- ZENV N/A
- INMB N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- INMB Health Care
- Exchange
- ZENV Nasdaq
- INMB Nasdaq
- Market Cap
- ZENV 63.3M
- INMB 112.0M
- IPO Year
- ZENV 2021
- INMB 2019
- Fundamental
- Price
- ZENV $1.62
- INMB $4.40
- Analyst Decision
- ZENV
- INMB Strong Buy
- Analyst Count
- ZENV 0
- INMB 2
- Target Price
- ZENV N/A
- INMB $21.00
- AVG Volume (30 Days)
- ZENV 72.4K
- INMB 198.5K
- Earning Date
- ZENV 11-18-2024
- INMB 10-31-2024
- Dividend Yield
- ZENV N/A
- INMB N/A
- EPS Growth
- ZENV N/A
- INMB N/A
- EPS
- ZENV N/A
- INMB N/A
- Revenue
- ZENV $173,594,726.00
- INMB $42,000.00
- Revenue This Year
- ZENV $25.56
- INMB N/A
- Revenue Next Year
- ZENV $6.02
- INMB N/A
- P/E Ratio
- ZENV N/A
- INMB N/A
- Revenue Growth
- ZENV 23.49
- INMB N/A
- 52 Week Low
- ZENV $1.00
- INMB $4.32
- 52 Week High
- ZENV $3.88
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- ZENV 54.93
- INMB 37.57
- Support Level
- ZENV $1.61
- INMB $4.74
- Resistance Level
- ZENV $1.78
- INMB $5.16
- Average True Range (ATR)
- ZENV 0.12
- INMB 0.38
- MACD
- ZENV -0.00
- INMB -0.05
- Stochastic Oscillator
- ZENV 48.48
- INMB 5.56
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.